Software-Aided Imaging for Liver Cancer Ablation

This trial tests a software-aided imaging system, such as Morfeus, to determine if it can enhance the accuracy of ablation therapy, which uses heat to destroy cancer cells, for liver tumors. The goal is to ensure complete coverage and effective treatment of the tumor during the procedure. Participants will be divided into two groups: one receiving standard ablation care and the other using the software-aided imaging for potentially improved results. Eligible participants may have up to three liver tumors and plan to undergo thermal ablation. Those already dealing with liver tumors and considering ablation might find this trial worth exploring. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research has shown that software-aided imaging systems, such as Morfeus, hold promise for improving liver cancer ablation. Ablation is a treatment that removes or destroys tumors. Studies have demonstrated that these software tools help doctors see and confirm the areas they treat during ablation more clearly.

A review of various studies found that the success rate of using these tools immediately after ablation ranged from 81.3% to 100%. This indicates that, in many cases, the software helped ensure the tumor was fully treated. Importantly, these studies identified that using software to check treatment borders is crucial for reducing risk.

Researchers are excited about software-aided imaging for liver cancer ablation because it could enhance the precision of standard ablation therapy. Unlike typical treatments that rely solely on the physician's skill and standard imaging, this approach uses advanced software to guide the procedure, potentially increasing accuracy and effectiveness. This innovation could improve outcomes by precisely targeting cancer cells while preserving healthy tissue, offering hope for better patient recovery and survival rates.

Research shows that software tools like Morfeus can enhance the accuracy of liver tumor treatments. In this trial, one group of participants will receive standard care ablation, while another group will receive standard care ablation with software-aided imaging using Morfeus. Studies have found that this technology ensures the entire tumor is targeted and treated. Accurate targeting is crucial because it reduces the risk of missing cancer cells during the procedure. Evidence suggests that these tools can lead to better outcomes by ensuring full tumor coverage. Additionally, accurate imaging helps verify the success of the treatment immediately after completion. Overall, these tools could improve liver tumor treatments by ensuring complete tumor treatment.¹²³⁴⁵